Muhammad Z Khan1, Muhammad U Khan1, Muhammad Bilal Munir2,3, Safi U Khan1, Mohammed Osman2, Sudarshan Balla2. 1. Department of Medicine, West Virginia University, Morgantown, West Virginia, USA. 2. Division of Cardiovascular Medicine, West Virginia University Heart & Vascular Institute, Morgantown, West Virginia, USA. 3. Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California, USA.
Abstract
OBJECTIVE: Even in high-risk trials pertaining to transcatheter aortic valve replacement (TAVR), patients with end-stage liver disease (ESLD) have been under-represented. We sought to study this population group from a large national United States population database. METHODS: We used National Inpatient Sample (NIS) database from January 2005 to August 2015. Patients with ESLD were extracted using Goldberg's algorithm. Propensity match analysis was done for comparative analysis between surgical aortic valve replacement (SAVR) and TAVR groups. Logistic regression analysis was used for predictors of in-hospital mortality. RESULTS: Out of 309,959 ESLD patients, 1,375 underwent aortic valve replacement and 1,199 patients were included in our study. Mean age was 66.1 (SD, 9.1) years. In matched data, the in-hospital mortality was 5.5% in TAVR group when compared to 19.4% in SAVR group. Ventilator use (16.1 vs. 27.2%, p < .01), tracheostomy (<4 vs. 7.2%, p < .01), and vasopressin use (0 vs. 7.4%, p < .01) were utilized less in TAVR group as compared to SAVR group. The proportion of TAVR has increased from almost zero in 2011 to 51.3% in 2015. Mean cost for hospital stay has increased in SAVR group (from 254,427$ in 2005 to 321,791$ in 2015, p < .01). Similarly, a large decrease in length of stay has been observed for TAVR group (14.5 days in 2011 to 5.4 days in 2015, p < .01). TAVR (odds ratios [OR]: 0.42, 95% confidence interval [CI]: 0.20-0.87, p = .02) was associated with lower in-hospital mortality. CONCLUSION: TAVR was associated with lower in-hospital mortality, morbidity, and resource utilization in high-risk ESLD patients.
OBJECTIVE: Even in high-risk trials pertaining to transcatheter aortic valve replacement (TAVR), patients with end-stage liver disease (ESLD) have been under-represented. We sought to study this population group from a large national United States population database. METHODS: We used National Inpatient Sample (NIS) database from January 2005 to August 2015. Patients with ESLD were extracted using Goldberg's algorithm. Propensity match analysis was done for comparative analysis between surgical aortic valve replacement (SAVR) and TAVR groups. Logistic regression analysis was used for predictors of in-hospital mortality. RESULTS: Out of 309,959 ESLDpatients, 1,375 underwent aortic valve replacement and 1,199 patients were included in our study. Mean age was 66.1 (SD, 9.1) years. In matched data, the in-hospital mortality was 5.5% in TAVR group when compared to 19.4% in SAVR group. Ventilator use (16.1 vs. 27.2%, p < .01), tracheostomy (<4 vs. 7.2%, p < .01), and vasopressin use (0 vs. 7.4%, p < .01) were utilized less in TAVR group as compared to SAVR group. The proportion of TAVR has increased from almost zero in 2011 to 51.3% in 2015. Mean cost for hospital stay has increased in SAVR group (from 254,427$ in 2005 to 321,791$ in 2015, p < .01). Similarly, a large decrease in length of stay has been observed for TAVR group (14.5 days in 2011 to 5.4 days in 2015, p < .01). TAVR (odds ratios [OR]: 0.42, 95% confidence interval [CI]: 0.20-0.87, p = .02) was associated with lower in-hospital mortality. CONCLUSION: TAVR was associated with lower in-hospital mortality, morbidity, and resource utilization in high-risk ESLDpatients.
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Susheel K Kodali; Mathew R Williams; Craig R Smith; Lars G Svensson; John G Webb; Raj R Makkar; Gregory P Fontana; Todd M Dewey; Vinod H Thourani; Augusto D Pichard; Michael Fischbein; Wilson Y Szeto; Scott Lim; Kevin L Greason; Paul S Teirstein; S Chris Malaisrie; Pamela S Douglas; Rebecca T Hahn; Brian Whisenant; Alan Zajarias; Duolao Wang; Jodi J Akin; William N Anderson; Martin B Leon Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: Michael J Reardon; David H Adams; Neal S Kleiman; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Joon Sup Lee; James B Hermiller; Stan Chetcuti; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John V Conte; Jon R Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2015-06-05 Impact factor: 24.094
Authors: Kenneth A McLean; Thomas M Drake; Alessandro Sgrò; Julian Camilleri-Brennan; Stephen R Knight; Riinu Ots; Anya Adair; Stephen J Wigmore; Ewen M Harrison Journal: Transpl Int Date: 2019-03-20 Impact factor: 3.782
Authors: Daniel Wendt; Philipp Kahlert; Ali Canbay; Stephan Knipp; Martin Thoenes; Gordina Cremer; Fadi Al-Rashid; Rolf-Alexander Jánosi; Karim El-Chilali; Markus Kamler; Mohamed El Gabry; Philipp Marx; Daniel Sebastian Dohle; Konstantinos Tsagakis; Jaroslav Benedik; Guido Gerken; Tienush Rassaf; Heinz Jakob; Matthias Thielmann Journal: Ann Thorac Surg Date: 2017-06-01 Impact factor: 4.330
Authors: Thomas G Gleason; Michael J Reardon; Jeffrey J Popma; G Michael Deeb; Steven J Yakubov; Joon S Lee; Neal S Kleiman; Stan Chetcuti; James B Hermiller; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John V Conte; Mubashir Mumtaz; Jae K Oh; Jian Huang; David H Adams Journal: J Am Coll Cardiol Date: 2018-09-21 Impact factor: 24.094